CRVS - コルバス・ファ―マシュ―ティカルズ (Corvus Pharmaceuticals Inc.) コルバス・ファ―マシュ―ティカルズ

 CRVSのチャート


 CRVSの企業情報

symbol CRVS
会社名 Corvus Pharmaceuticals Inc (コルバス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コーバス・ファーマスーティカル(Corvus Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は免疫腫瘍療法の開発と商品化に従事する。同社は免疫チェックポイントを阻止し、免疫T細胞を再プログラミングする薬物と抗体を開発する。同社は4つの免疫腫瘍学プログラムのパイプラインがあり、そのうち3つは免疫応答を調節するアデノシン - 癌軸に焦点を当てる。同社のリード製品候補であるCPI-444は免疫チェックポイントであるアデノシンに対するA2A受容体の経口・小分子アンタゴニストである。他の製品にはモノクローナル抗CD73抗体であるアデノシン産生阻害剤、アデノシンA2Bアンタゴニスト及びインターロイキン-2(IL-2)誘導性T細胞キナーゼ(ITK)阻害剤を含む。   コルバス・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品企業。がん治療のための新薬の開発・商品化に注力する。主に、アデノシンの生産を阻害及び抑制することで、免疫反応の調整を促す免疫腫瘍学のパイプラインを構築。また、T細胞の活性化と分化を調節するための治療薬も開発中。本社はカリフォルニア州。   Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.
本社所在地 863 Mitten Road Suite 102 Burlingame CA 94010 USA
代表者氏名 Richard A. Miller リチャード・A・ミラー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 650-900-4520
設立年月日 41640
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 55人
url www.corvuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/crvs
adr_tso
EBITDA EBITDA(百万ドル) -51.16600
終値(lastsale) 8.58
時価総額(marketcap) 250517613.06
時価総額 時価総額(百万ドル) 248.47380
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 115.24880
当期純利益 当期純利益(百万ドル) -50.57800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corvus Pharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $25.9M. Lower net loss reflects Research and development - Balancing val decrease of 18% to $20.3M (expense) General and administrative - Balancing decrease of 18% to $3.1M (expense) Interest income increase from $374K to $970K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.03.

 CRVSのテクニカル分析


 CRVSのニュース

   Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target  2021/05/27 19:50:51 Seeking Alpha
   Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference  2021/05/25 20:05:00 GlobeNewswire
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET.
   Zacks: Brokerages Expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Announce -$0.35 Earnings Per Share  2021/05/11 16:56:41 Transcript Daily
Analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will post earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.36). Corvus Pharmaceuticals posted earnings per share of []
   Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target  2021/05/27 19:50:51 Seeking Alpha
   Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference  2021/05/25 20:05:00 GlobeNewswire
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET.
   Zacks: Brokerages Expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Announce -$0.35 Earnings Per Share  2021/05/11 16:56:41 Transcript Daily
Analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will post earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.36). Corvus Pharmaceuticals posted earnings per share of []
   Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target  2021/05/27 19:50:51 Seeking Alpha
   Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference  2021/05/25 20:05:00 GlobeNewswire
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET.
   Zacks: Brokerages Expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Announce -$0.35 Earnings Per Share  2021/05/11 16:56:41 Transcript Daily
Analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will post earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.36). Corvus Pharmaceuticals posted earnings per share of []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コルバス・ファ―マシュ―ティカルズ CRVS Corvus Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)